Charles Schwab Investment Management Inc. Grows Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Charles Schwab Investment Management Inc. increased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 5.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,103,326 shares of the biopharmaceutical company’s stock after acquiring an additional 57,125 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.53% of Sangamo Therapeutics worth $956,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC acquired a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth about $67,000. Meritage Portfolio Management increased its position in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Sangamo Therapeutics during the second quarter valued at about $89,000. Wealth Enhancement Advisory Services LLC raised its position in Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the period. Finally, Marshall Wace LLP lifted its stake in Sangamo Therapeutics by 56.3% during the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 207,476 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Wall Street Analyst Weigh In

SGMO has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, December 10th. Barclays increased their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Friday, December 13th. Finally, StockNews.com upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Sangamo Therapeutics Trading Up 6.6 %

Sangamo Therapeutics stock opened at $2.82 on Wednesday. The stock has a market cap of $588.38 million, a P/E ratio of -3.76 and a beta of 1.15. The company has a fifty day simple moving average of $1.88 and a 200-day simple moving average of $1.10. Sangamo Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. During the same period in the prior year, the firm posted ($0.34) EPS. As a group, sell-side analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.